Transparency Initiative to provide more information on FDA regulation and drug development

被引:0
|
作者
Wechsler, Jill
机构
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:232 / 233
页数:2
相关论文
共 50 条
  • [11] The FDA critical path initiative and its influence on new drug development
    Woodcock, Janet
    Woosley, Raymond
    ANNUAL REVIEW OF MEDICINE, 2008, 59 : 1 - 12
  • [13] Transparency of drug information
    Kopp, Christophe
    AUSTRALIAN PRESCRIBER, 2006, 29 (03) : 62 - 62
  • [15] Catalyzing the Critical Path Initiative: FDA's Progress in Drug Development Activities
    Parekh, A.
    Buckman-Garner, S.
    McCune, S.
    ONeill, R.
    Geanacopoulos, M.
    Amur, S.
    Clingman, C.
    Barratt, R.
    Rocca, M.
    Hills, I.
    Woodcock, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (03) : 221 - 233
  • [16] Selected proceedings of the NICHD/FDA newborn drug development initiative: Part II
    Giacoia, George R.
    Mattison, Donald R.
    CLINICAL THERAPEUTICS, 2006, 28 (09) : 1337 - 1341
  • [17] Transparency Initiative by the FDA's Center for Drug Evaluation and Research (CDER): Two qualitative studies of Public Perceptions
    Chakraborty, Sweta
    Lofstedt, Ragnar
    EUROPEAN JOURNAL OF RISK REGULATION, 2012, 3 (01) : 57 - 71
  • [18] FDA proposes changes in drug information regulation to prevent congressional action
    Wechsler, J
    FORMULARY, 1996, 31 (07) : 623 - 624
  • [19] Drug development and regulation could be affected by limited resources at FDA
    Wechsler, Jill
    FORMULARY, 2008, 43 (02) : 82 - 83
  • [20] Drug price transparency initiative: A scoping review
    Ahmad, Nur Sufiza
    Makmor-Bakry, Mohd
    Hatah, Ernieda
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2020, 16 (10): : 1359 - 1369